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INTRODUCTION & OBJECTIVES: Urothelial tumors of upper urinary tract are ranked among the most common types of cancers worldwide.
The current standard therapy to prevent recurrence is intravesical Bacillus Calmette–Guerin (BCG) immunotherapy, but it presents several
disadvantages such as BCG failure and intolerance. Another way is to use chemotherapy, which is generally better tolerated that BCG. In
this case, drugs such as epirubicin, doxorubicin, paclitaxel and gemcitabine are used. Nevertheless, intravesical chemotherapy only
prevents recurrence in the short-term. These failings can be partially attributed to the short residence time and low bioavailability of the drug
within the upper urinary tract and the cancer cells, resulting in a need for frequent drug instillation. To avoid these problems, biodegradable
ureteral stents impregnated by supercritical fluid CO2 (SCF) with each of the four anti-cancer drugs were produced.
MATERIAL & METHODS: Four formulations with different concentrations of gelatin and alginate and  crosslink agent were tested and
bismuth was added to confer radiopaque properties to the stent. The preliminary in vivo validation studies in female domestic pigs was
conducted at the University of Minho, Braga, after formal approval by the institution’s review board and in accordance with its internal ethical
protocol for animal experiments.
Paclitaxel, epirubicin, doxorubicin and gemcitabine were impregnated in the stents and the release kinetics was measured in artificial urine
solution (AUS) for 9 days by UV spectroscopy in a microplate reader. The anti-tumoral effect of the developed stents in transitional cell
carcinoma (TCC) and HUVEC primary cells, used as control, was evaluated.
RESULTS: The in vivo validation of this second-generation of ureteral stents performed was herein demonstrated. Biodegradable ureteral
stents were placed in the ureters of a female pigs, following the normal surgical procedure. The animals remained asymptomatic, with
normal urine flow.  The in vitro release study in AUS of the stent impregnated showed a
higher release in the first 72h for the four anti-cancer drugs impregnated after this time the plateau was achieved and the stent degraded
after 9 days.
The direct and indirect contact of the anti-cancer biodegradable stents with the TCC and HUVEC cell lines confirm the anti-tumor effect of
the stents impregnated with the four anti-cancer drugs, reducing around 75% of the viability of the TCC cell line after 72h and no killing
effect in the HUVEC cells.
CONCLUSIONS: The use of biodegradable ureteral stent in urology clinical practice not only reduce the stent-related symptoms but also
open new treatment therapy’s, like in urothelial tumors of upper urinary tract.
Furthermore, we have demonstrated the clinical validation in vivo pig model. This study has thus shown the killing efficacy of the anti-cancer
drug eluting biodegradable stents in vitro for the TCC cell line, with no toxicity observed in the control, non-cancerous cells.The direct and
indirect contact of the anti-cancer biodegradable stents with the TCC and HUVEC cell lines confirm the anti-tumor effect of the stents
impregnated with the four anti-cancer drugs, reducing around 75% of the viability of the TCC cell line after 72h and no killing effect in the
HUVEC cells. This study has thus shown the killing efficacy of the anti-cancer drug eluting biodegradable stents in vitro for the TCC cell
line, with no toxicity observed in the control, non-cancerous cells.
